Early Metabolic Risk in Childhood Brain Cancer Survivors With Childhood-Onset Growth Hormone Deficiency
Authors' conclusion
Among CBC survivors with childhood-onset GHD, dyslipidemia, impaired glucose metabolism, and reduced BMD are highly prevalent in very early adulthood. Suprasellar tumors show a distinct metabolic vulnerability.
Study context
- Population
- Childhood brain cancer (CBC) survivors (excluding craniopharyngiomas) with childhood-onset growth hormone deficiency (GHD) treated with GH in childhood, aged ≥18 years in January 2025, after transition into adulthood; 1 pediatric endocrinology, 2 pediatric oncology and 1 adult endocrinology departments
- Participants
- 91 survivors
- Outcome
- Metabolic and endocrine outcomes: lipid profile, HbA1c, BMD, BMI and pituitary hormone status
Methodological detailsmulticentric
- Multicentric
Main finding
As reported in the abstract
Prevalence of metabolic outcomes
Dyslipidemia
54 of 91
59.4%
Prediabetes
9 of 91
10%
Reduced bone mineral density (BMD) (osteopenia or osteoporosis)
62 of 90
68.6%
Remained GHD at transition
71 of 91
78%
Observational data: associations, not effects.
Further findings
BMI and HbA1c: suprasellar vs non-suprasellar tumours
- BMI and HbA1c significantly higher in the suprasellar than the non-suprasellar subgroup
Dyslipidaemia by tumour location
- Dyslipidemia not associated with tumor location
Persistent GHD on GH therapy vs persistent GHD without therapy vs transient GHD
- No significant differences among persistent GHD on GH therapy, persistent GHD without therapy, or transient GHD
Original publication
Early Metabolic Risk in Childhood Brain Cancer Survivors With Childhood-Onset Growth Hormone Deficiency. Endocr Pract. Published 4 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →